RESPONSE TO DIFFERENT CONVENTIONAL INTERFERONS IN TREATMENT OF CHRONIC HEPATITIS C
AbstractBackground: Sustained virological response to interferon therapy is a great challenge for patients ofchronic Hepatitis C. Over 20 brands of interferons are available in the local market with each claimingover 80% response and a wide variation in the cost thus creating confusion for treating physicians as towhich drug should be selected. Methods: Chronic Hepatitis C patients attending outpatients departmentof Pakistan Medical Research Centre JPMC from January 1998–December 2010 were evaluated.Complete blood count, liver function tests, serum proteins, HCV-RNA were done in all cases beforestarting therapy. Side effects were also noted. Results: Total of 851 cases received interferon 3 MIUthree times a week for 6 months. There were 638 (75%) males and 213 (25%) females, mean age was36.1±10.4 years. All were HCV-RNA positive prior to treatment, at the end of 6 months 666 (78.3%)became negative while 185 (21.7%) were non-responders with positive HCV RNA. End of treatmentresponse (ETR) showed 84.7% with Bioferon (Argentina), 83.8% Hebron (Cuba), 82.2% INF(Argentina), 82.1% Ceron (China), 81% Viteron (Korea), 80.7% Leveron (Argentina), 81.5%Hepaferon, 79.1% Anferon (China), 77.4% Intron (Belgium), 75% Green alpha (Korea), 74% Roferon(Switzerland), 67.3% Uniferon (Lithuania), and 68.4% with others. Post-treatment 211 cases were lost tofollow-up. In remaining 358/640 (55.9%) negative for HCV-RNA, at six months follow up, whereas 98(15.3%) relapsed. Sustained virological response (SVR) Ceron 68.2%, Hebron 66.3%, Bioferon 65.2%,Leveron 60.5%, Intron 60.3%, Viteron 57%, Anferon 53.3%, Green alpha, Roferon, Hepaferon, andothers 50%, INF 48.5% and Uniferon 41.9%. Average cost of these interferons was Rs. 6,000/month,except Hepaferon 5,000/month, Roferon 10,600/month. Conclusions: ETR ranged from 74–84.7% andSVR 41.9% to 68.2% and >60% SVR was observed with Ceron, Hebron, Bioferon, Leveron, Intron andwere cost effective.Keywords: Conventional interferon, response, chronic Hepatitis C.
Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence
of hepatitis B and C viral infections in Pakistan: findings of a
national survey appealing for effective prevention and control
measures. East Mediterr Health J 2010;16 Suppl:S15-23.
Ahmed W, Qureshi H, Arif A, Alam SE. Changing trend of viral
hepatitis –A twenty-one year report from Pakistan Medical
Research Council, Research Centre, Jinnah Postgraduate Medical
Centre, Karachi. J Pak Med Aassoc 2010:60(2):86–9.
Rehman I, Idrees M, Ali M, Ali L, Butt S, Hussain A, et al.
Hepatitis C virus genotype 3a with phylogenetically distinct
origin is circulating in Pakistan. Genet Vaccines Ther 2011;9:2.
Farooqi JI, Farooqi RJ. Efficacy of conventional Interferon alpha-
b plus Ribavirin combination in the treatment of Chronic
Hepatitis C naïve patients. Rawal Med J 2005;30:9–11.
Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A,
Peters M, et al. Treatment of chronic non-A, non-B hepatitis with
recombinant human alpha interferon. A preliminary report. N
Engl J Med 1986;315:1575–8.
Tong MJ, Blatt IM, McHutchison JG, Co RL, Conrad A.
Prediction of response during interferon alfa 2b therapy in
chronic hepatitis C patients using viral and biochemical
characteristics: A comparison. Hepatology 1997;26:1640–5.
Ferrell GC, Bacon BR, Goldin RD. Lymphoblastoid Interferon
alfa-n1 improves the long term response to a 6-month course of
treatment in chronic hepatitis C compared with recombinant
interferon alfa-2b: Results of an international randomised
controlled trial, Clinical Advisory Group for the Hepatitis C
Comparative study. Hepatology 1998;27:1121–7.
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee
WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination
with Ribavirin as initial treatment for chronic hepatitis C.
Hepatitis Interventional Therapy Group. N Engl J Med
Devis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo
C, et al. Interferon alfa-2b alone or in combination with Ribavirin
for the treatment of relapse of chronic hepatitis C. International
Hepatitis Interventional Therapy Group. N Engl J Med
Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid M, Hoofnagle
JH. 10-years follow-up after interferon-alpha therapy for chronic
hepatitis C. Hepatology 1998;28:1121–7.
Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung
SN, Seef LB. Tolerance and efficacy of oral Ribavirin treatment
of chronic hepatitis C: a multicenter trial. Hepatology
J Ayub Med Coll Abbottabad 2012;24(3-4)
Kjaergard LL, Krogsgaad K, Gluud C. Interferon alfa with or
without Ribavirin for chronic hepatitis C: systematic review of
randomised trials. BMJ 2001;323:1151–5.
Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al.
Long-term efficacy of Ribavirin plus interferon alfa in the
treatment of chronic hepatitis C. Gastroenterology
Pol S, Nalpas B, Bourliere M, Couzigou P, Tan A, Abergel A, et
al. Combination of Ribavirin and interferon-alfa suppresses high
dose of interferon-alfa alone in patients with genotype-1b related
chronic hepatitis C. Hepatology 2000;31:1338–44.
Tayyab GN, Haque I, Zafar S. Rapid virological response (RVR)
and early virological response (EVR) with standard Interferon
and Ribavirin for chronic HCV infection —An experience. J Pak
Med Assoc 2007;57:S-2.
Ahmed W, Qureshi H, Arif A, Ather R, Kiran. Is response of
Alpha 2A and 2B interferon same in Hepatitis C. J Pak Med
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis,
management and treatment of hepatitis C. AASLD practice
guidelines 2004. Available at: http//www.natap.org/2004/pdf/
Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J.
Pakistan Society of Gastroenterology. PSG Consensus Statement
on management of Hepatitis C virus infection 2003. J Pak Med